This limits the efficiency of therapeutic directed RNA editing applications where the target adenosine has a 5′ G, such as premature UGA termination codons like those arising from the R168X, R255X and R270X mutations in the MECP2 gene associated with Rett Syndrome (27). Here, MECP2 is linked to Rett syndrome.